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Abstract
Orthopaedic disorders are very frequent, globally found and often partially unresolved despite the substantial
advances in science and medicine. Their surgical intervention is multifarious and the most favourable treatment is
chosen by the orthopaedic surgeon on a case-by-case basis depending on a number of factors related with the
patient and the lesion. Numerous regenerative tissue engineering strategies have been developed and studied
extensively in laboratory through in vitro experiments and preclinical in vivo trials with various established animal
models, while a small proportion of them reached the operating room. However, based on the available literature,
the current strategies have not yet achieved to fully solve the clinical problems. Thus, the gold standards, if existing,
remain unchanged in the clinics, notwithstanding the known limitations and drawbacks. Herein, the involvement of
regenerative tissue engineering in the clinical orthopaedics is reviewed. The current challenges are indicated and
discussed in order to describe the current disequilibrium between the needs and solutions made available in the
operating room. Regenerative tissue engineering is a very dynamic field that has a high growth rate and a great
openness and ability to incorporate new technologies with passion to edge towards the Holy Grail that is
functional tissue regeneration. Thus, the future of clinical solutions making use of regenerative tissue engineering
principles for the management of orthopaedic disorders is firmly supported by the clinical need.
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Facing the current challenges
There are numerous challenges that reason the disequi-
librium between the clinical demand and the functional
supply which are discussed in this review. The chal-
lenges and outstanding issues are multifarious and
multifactorial. However, from the functional point of
view, they fall under the umbrella of the expectation
from a typical regenerative tissue engineering product to
perform better over time (in both short- and long-term)
than the day of implantation. This fact naturally stems
from the typical perception of regenerative tissue engin-
eering (i.e. achieving tissue regeneration through matrix
synthesis of cells and degradation of scaffold), and re-
veals why there is a big difference between materials
science and biomaterials science on accomplishing their
goals. This path to our ultimate goal, our dream, has
been very expensive and very time-consuming.
Typically, regenerative tissue engineering employs cells
(Huang et al. 2016), scaffolds (Hollister 2009a; Roffi et al.
2017) or hydrogels (Annabi et al. 2014; Bacelar et al.
2017), and growth/stimulating factors (Gothard et al.
2014; Kwon et al. 2016) while these components have also
been used alone for several reasons including relative
regulatory, practical and economical convenience. With
respect to the involvement of cells in the regenerative
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tissue engineering, the strategies can comprise the recruit-
ment of the patient’s own cells or the transplantation of
cells (Fig. 1). As soon as the cells are in contact with a
scaffold, biology “differentiates” into materiobiology, and
the behaviour of the cells depend on the features of the
scaffold including but not limited to micro-structure, sur-
face properties, and mechanical properties. Besides, the
influence of ex vivo culturing of the isolated cells, and the
presence of signalling factors affect the cell behaviour. In-
structive scaffold strategies promote tissue regeneration
with recruitment of scaffold-driven endogenous stem cells
that can provide regenerative micro-environments thanks
to their paracrine activity (Caplan 2007; Karp and Teo
2009). This strategy comes with the advantages in terms
of surgery, cost, regulations, and commercialisation thanks
to being an off-the-shelf product (Martin et al. 2007). The
typical regenerative tissue engineering strategy involves
the scaffolds seeded with ex vivo cultured cell and the
cell-scaffold is either maturated in body after implantation
assuming the body of the patient as a bioreactor, or culti-
vated in a bioreactor prior implantation. This strategy
lacks the advantages of acellular scaffolds but have a great
theoretical potential of functional tissue regeneration. The
recruitment of the cells, i.e. endogenous cell homing
(Chen et al. 2011; Fong et al. 2011; Karp and Teo 2009;
Ko et al. 2013) can be mediated by recruiting factors that
are signalling molecules, controlled release of navigational
cues in addition to the cues of an instructive scaffold with
the rationale of enhancing the intrinsic in situ tissue re-
generation, and has been studied in animal models (Burks
et al. 2013; Huang et al. 2014; Lee et al. 2008; Shen et al.
2010). Understanding the extremely complex pathways
and interactions of the components will bring this strategy
a step closer to develop robust clinical treatments.
A regenerative tissue engineering product needs to be
extensively studied in vitro (Caddeo et al. 2017), in vivo
(McCullen et al. 2011) with animal models (Madry et al.
2015; Moran et al. 2016), and in silico (Díaz-Zuccarini
and Lawford 2010; Geris 2014; Geris et al. 2016) when-
ever possible, before initiating a trial in patients to as-
sure “Primum non nocere” (First do no harm) that is
present in the Hippocratic oath. Over the last two de-
cades, numerous papers have been published on the tis-
sue engineering of bone (Amini et al. 2012; Oryan et al.
2014), cartilage (Huang et al. 2016; Hunziker et al.
2015), osteochondral tissue (Cengiz et al. 2014; Yan et al.
2015), meniscus (Cengiz et al. 2017b; Cengiz et al.
2017e), tendons (Walden et al. 2017; Youngstrom and
Fig. 1 Clinically relevant orthopaedic regenerative tissue engineering strategies. Cells, scaffolds, and signalling factors are the main components
of regenerative tissue engineering. Ex vivo cultured cells can be transplanted with or without cultivation in a bioreactor or an in situ tissue
regeneration strategy can be followed for endogenous cell homing with the recruited factors such as instructive scaffolds and/or signalling
factors can be used. Strong evidence from in vitro and preclinical experiments are needed prior to initiating a clinical trial in humans. Strategies
should be developed in a translational research environment with the involvement and communication all stakeholders since the beginning
which include orthopaedic surgeons, academic scientists, funding bodies, and regulatory bodies
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Barrett 2015), ligaments (Hogan et al. 2015; Mengsteab
et al. 2016), and muscles (Grasman et al. 2015; Sicari et
al. 2015). The original works mostly involve in vitro
studies, with a certain share of preclinical animal studies.
Studies with large animal models are required for the
market approval of the product, however, the human
body is not the same as any animal model it is clear that
no animal model accurately mimics the human condi-
tion (Madry et al. 2014).
The ultimate goal of the researcher and of the ortho-
paedic surgeon in the field is to achieve tissue regener-
ation to minimise the post-surgery health problems,
speed up the patient’s return to activity, and avoid the
need of subsequent surgical interventions.
Several distinct tissues are involved in orthopaedics
and rigorously require specific considerations since each
tissue has its own nature regarding biology and bio-
mechanics alongside its interfaces (Cross et al. 2016; Rao
et al. 2016; Tellado et al. 2015) with the adjacent tissues.
Therefore, the level of success of tissue regeneration is
related to the nature of the tissue (Huey et al. 2012). For
instance, although vascularised tissues have a substantial
self-healing capacity for minor lesions, for large lesions
regenerative tissue engineering tackles the problems re-
garding hypoxia, vascularisation, and angiogenesis.
To stimulate the cell function and enhance the per-
formance, bioreactors have been studied (Jin et al. 2015;
Martin et al. 2009; Ravichandran et al. 2017). Better
results can be achieved compared with the static cell
culture for instance increased matrix synthesis, mineral-
isation, expression of specific genes, cell proliferation,
and differentiation. Based on the design and application,
various bioreactors can be developed proving a range of
mechanical, chemical, or electrical stimulation in
addition to the features of a static cell culture incubator.
However, the diffusion of bioreactors to the clinics are
limited probably due to the associated costs and applica-
tion related issues (Salter et al. 2011). It was estimated
that bioreactor-cultured bone grafts would have a cost
around 10–15 thousand US dollars, that is comparable
to other cellular treatments (Salter et al. 2011).
The cell sources and types can be diverse included but
not limited to stem cells (Narayanan et al. 2017) such as
adipose or bone marrow-derived stem cells, or primary
differentiated cells isolated from a particular tissue, the
critical point being to employ cells capable of producing
the matrix of that particular tissue. The cells regulate/
alter their behaviour depending on the niche that they
are in, like in the human body. Thus, the biology in a
cell culture flask does not remain the same when the
cells are in contact with a scaffold. Cells sense almost
everything about the scaffolds, including but not limited
to chemistry/composition, nano−/micro−/macro-structure
such as porosity, pore size and interconnectivity, surface/
volume ratio, topography, degradation profile, and mech-
anical properties such as stiffness (Li et al. 2017; Zajac and
Discher 2008). The surface of a scaffold is of major im-
portance since it is interfacing with the cells where several
interactions take place, including fluid and protein adhe-
sion, attachment, adhesion and spreading of cells (Meyer
and Wiesmann 2006; Stevens and George 2005). Control-
ling such features of a scaffold would influence the cell
function for instance adhesion, growth, matrix synthesis,
differentiation, and alignment. This evidences that a scaf-
fold is not a cell transporting vehicle, but it belongs to the
niche of the cells that decode the scaffold’s features
(Pennesi et al. 2011). Moreover, all these mentioned fea-
tures of the scaffold affect the clinical treatment outcome
(Cengiz et al. 2017b). Thus, tissue engineering should re-
solve the unclear cell-scaffold relations and address the
scaffold-associated outstanding challenges to ease the
translation of tissue-specific cell-scaffolds constructs from
laboratory to operating room. Notwithstanding, being a
pillar of regenerative tissue engineering, and the need for
personalised orthopaedic implants(Cengiz et al. 2016;
Cengiz et al. 2017c; Oner et al. 2017), the use of scaffolds
can be questioned (Huey et al. 2012) since tissue genesis
occurs with self-assembly/organisation via signalling and
cell-cell contact without any exogenous scaffold in utero.
Self-assembly occurs through the minimisation of free
energy via cell-cell interactions and the cells unite into a
cohesive structure and act as a scaffold for each other
(Athanasiou et al. 2013; Hu and Athanasiou 2006).
Despite our advanced knowledge and expertise (Cengiz
et al. 2017b; Fernandez-Yague et al. 2015; Henkel et al.
2013; Hogan et al. 2015; Hunziker et al. 2015; Qazi et al.
2015; Walden et al. 2017; Yan et al. 2015), the current
treatments have a range of success and most of them (if
not all) are far from “ideal” since they do not systematic-
ally provide functional tissue regeneration. Although there
is no firm recommendation on the best available regenera-
tive tissue engineering construct strategy, we have been
learning from all those studies and trials. Regenerative
tissue engineering will be able to solve only a portion of
clinical challenges, if it can eventually, given the fact that
there are indications/contra-indications for the use of
regenerative tissue engineering products. While different
regenerative tissue engineering strategies/products are
competing with each other, from the clinical perspective,
they all compete with the conventional treatments that
the surgeon is experienced with and are safer options re-
garding economics and regulations.
The report from Hollister (Hollister 2009b) clearly il-
lustrates the gap between regenerative tissue engineering
research and clinical translation in which the need of a
change in research paradigm was highlighted and the
difficulty of covering the high costs discussed. It is diffi-
cult for a two-step surgical treatment to be favoured
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over one-step surgical treatment provided similar out-
comes at much lower costs (Mollon et al. 2013; Mundi
et al. 2016). Bayon et al. (Bayon et al. 2014) reviewed the
critical role of partnering in the clinical translation of
cell-based advanced therapy medicinal products which
was discussed and highlighted in the Tissue Engineering
& Regenerative Medicine International Society-Europe
Industry Symposium in 2013. Additionally, the report
from Madry et al. (Madry et al. 2014) from the “Where
Science meets Clinics” symposium in 2013 sponsored by
the AO Foundation (https://www.aofoundation.org) con-
veyed the perspectives of each stakeholder of the clinical
translation process of orthopaedic regenerative tissue en-
gineering which include academic scientists, clinicians,
industry, and regulatory bodies, and stressed the need
for “translational research environment” that is the com-
munication of all stakeholders throughout the project.
The poor translation of regenerative tissue engineering
to the clinics has been causing a demand and supply dis-
equilibrium, and the tremendous effort of tissue engi-
neers remain somewhat unappreciated. Apparently, it
has been recognised that having a fundamental change
in the clinical intervention of orthopaedic disorders is
not a short-term task. Besides, it is evident that success
in the laboratory is a critical determinant for a human
trial. However, the success of laboratory experiments can
be maximised, and the outcomes of the research can be
enhanced when academic researchers and clinicians
work together and make joint efforts throughout the de-
velopment of the clinical solution including the early
stages of idea formation. Since the time of the idea gen-
eration and proposal preparation, clinical relevance with
defined indications and efficacy measures are needed to
create a roadmap for on the envisioned solution. Besides,
regulatory requirements (Grieshober et al. 2017; Lysaght
et al. 2017) should be known by the research team mem-
bers from the beginning. For Europe, the Regulation
(EC) no 1394/2007 of the European Parliament and of
the Council of 13 November 2007 on Advanced Therapy
Medicinal Products (ATMPs), which is an optional classi-
fication procedure, and amending Directive 2001/83/EC
and Regulation (EC) No 726/2004 is available on
http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=-
CELEX:32007R1394&from=EN. Well-organised preclinical,
clinical studies, especially multicenter, randomised clin-
ical trials, although very challenging (Büchler et al.
2011; Ergina et al. 2009; Lyman et al. 2016) are ex-
tremely costly by all means. However, this is the robust
way to study whether there is an evidence that regen-
erative tissue engineering solutions can be favoured
over comparator treatments for targeted clinical condi-
tions or not.
Thanks to their regenerative potential and regulatory
and practical advantage (Chahla et al. 2017), biologics
including platelet-rich plasma (PRP), bone marrow aspir-
ate concentrate, hyaluronic acid, and stem cells (Gobbi
et al. 2017; Narayanan et al. 2017) have been widely used
in orthopaedics (Gobbi et al. 2017; Musahl et al. 2017;
Utku et al. 2015) including for bone (Malhotra et al.
2013), cartilage (Nakasa et al. 2017), meniscus (Cengiz et
al. 2017a), muscle (Canata et al. 2017), tendons (Canata
et al. 2017), and ligaments (Gobbi and Whyte 2017).
Compared with the use of scaffolds or ex vivo cultured
cell therapies, the clinical use of PRP is of relative prac-
tical and/or regulatory convenience as it is autologous,
minimally obtainable, and relatively easy to apply. Given
the fact that there are numerous PRP usages (such as
preparation protocol, formulation, dosage, application
technique), there are inconsistencies in the clinical stud-
ies as systematically reviewed by Chahla et al. (Chahla et
al. 2017). The benefits of PRP depend on the context
(Andia and Maffulli 2013), and thus some studies disagree
with each other (Metcalf et al. 2013; Piuzzi et al. 2017).
Nourissat et al. (Nourissat et al. 2013) pointed out that
there is no evidence favouring the use of PRP in arthro-
scopic surgery while a meta-analysis (Sheth et al. 2012)
showed that there was no absolute evidence on the clinical
usefulness of PRP in orthopaedics.
Orthopaedic regenerative tissue engineering in
the operating room
Tendons and ligaments
To meet the extensive clinical needs regarding tendons
and ligaments, biomaterials (Table 1) have mainly been
used for repair augmentation rather than for direct
tissue regeneration since immediate mechanical proper-
ties are demanded as the need to overcome the known
limitations of grafts. It is not uncommon that the same
or similar biomaterials were used for tendons and
ligaments. The synthetic materials such as polytetra-
fluoroethylene (Gore-Tex Device; W.L. Gore, Flagstaff,
Arkansas) or Dacron Device (Stryker, Kalamazoo,
Michigan) were used in the past (Chen et al. 2015).
Polyethylene terephthalate (LARS ligament; LARS, Arc
sur Tille, Burgundy, France), and natural polymers such
as silk-based biomaterials (SeriACL graft; Serica Tech-
nologies, Medford, Massachusetts) as an alternative to
grafts (https://clinicaltrials.gov/ct2/show/record/NCT00
775892 and https://clinicaltrials.gov/ct2/show/NCT0049
0594) were tested, all of which having been manufac-
tured with textile technologies to achieve higher mech-
anical strength. For tendon repair, extracellular matrix
and synthetic polymers were envisaged (Derwin et al.
2006; Ricchetti et al. 2012; Smith et al. 2017). Patients
that received a polycarbonate polyurethane patch
(Biomerix, Fremont, CA) for rotator cuff repair augmen-
tation showed significant improvements in pain relief,
simple shoulder test, and American Shoulder and Elbow
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Surgeons shoulder scores with a 10% re-tear rate at the
12-months post-operation (Encalada-Diaz et al. 2011).
The use of Zimmer Collagen Repair Patch in the treat-
ment of extensive rotator cuff tears reported to provide
excellent pain relief with a moderate functional improve-
ment (Badhe et al. 2008). In a prospective, randomised
controlled trial with GraftJacket Regenerative Tissue
Matrix, intact repair ratios were reported to be in 85% in
the augmented group and 40% in the control group
(Barber et al. 2012). In a case-controlled study (Hernigou
et al. 2014), injection of bone marrow concentrates
containing mesenchymal stem cells as an adjunct therapy
during arthroscopy improved the healing of rotator cuff
with tendon integrity found in 87% of patients in the bone
marrow concentrate injection group versus 44% in the
control group (Hernigou et al. 2014). Based on the rando-
mised controlled trial performed by Ianotti et al. (Iannotti
et al. 2006), repair of massive chronic rotator cuff tears
was not recommended with Restore Orthobiologic Im-
plant (DePuy Orthopaedics; Warsaw, Indiana) since it did
not improve the clinical outcomes or tendon healing with
9 out of 15 cases healed in the control group while only 4
out of 15 cases healing in the augmentation group
(Iannotti et al. 2006). Moreover, Zheng et al. (Zheng et al.
2005) observed that patients who received Restore
Orthobiologic Implant for tendon repair displayed
swelling and severe pain at the implantation site. The
study critically analysed the implant through histology
and nested polymerase chain reaction. The authors
reported the presence of porcine cells and DNA mater-
ial in contrast to the way it was advertised, and in
animal studies, they observed inflammatory responses
characterised by massive lymphocyte infiltration (Zheng
et al. 2005).
In a case series with a minimum 2-year follow-up of
reconstruction of irreparable massive or full-thickness
2-tendon rotator cuff tears using Conexa, significant
improvement in pain, range of motion, strength, and
subjective outcome measures in patients with minimal
glenohumeral arthritis were reported (Gupta et al. 2013).
However, this study lacks the long-term results and
case-controls. X-Repair (poly-L-lactic acid) was used to
reinforce the surgical repair of large to massive rotator
cuff tears, and 83% and 78% of patients had important
functional improvement at 12 and 48 months post-surgery,
respectively (Proctor 2014). The use of a polyethylene ter-
ephthalate fibre mesh (Dacron; Dacron Xiros, Leeds, UK)
in the surgical augmentation of the symptomatic massive
rotator cuff tears provided pain relief and improved shoul-
der movement with a 90% of mean patient satisfaction
Table 1 Examples of commercial products for tendon repair
Product Company Biomaterial References
Ligament Advanced Reinforcement
System (LARS)
LARS (Arc sur Tille, France) Polyethylene terephthalate (Naim et al. 2011; Gao et al. 2010;
Dominkus et al. 2006)
GraftJacket Regenerative Tissue
Matrix
LifeCell (Branchburg, New Jersey;
distributed by Wright Medical
Technology, Arlington, Tennessee)
Processed human dermis (Wong et al. 2010; Bond et al. 2008;
Barber et al. 2012)
Restore Orthobiologic Implant DePuy Orthopaedics (Warsaw, Indiana) Collagen-based patch from
porcine small intestine
submucosa
(Iannotti et al. 2006; Walton et al.
2007; Zheng et al. 2005)
Zimmer Collagen Repair Patch
(formerly: Permacol - Tissue Science
Laboratories; Aldershot, Hampshire, UK)
Tissue Science Laboratories (Aldershot,
Hampshire, United Kingdom; distributed
by Zimmer, Warsaw, Indiana)
Processed porcine dermis (Badhe et al. 2008; Giannotti et al.
2014; Soler et al. 2007)
CuffPatch Bioengineered Tissue
Reinforcement
Organogenesis (Canton, Massachusetts;
marketed by Arthrotek, Warsaw, Indiana)
Multilayer sheet from
porcine small intestine
submucosa
(Abraham et al. 2000; Barber et al.
2006; Derwin et al. 2006)
X-Repair Synthasome (San Diego, California) Poly-L-lactic acid mesh (McCarron et al. 2010; Proctor 2014;
Smith et al. 2016)
Poly-Tape (Dacron) Neoligaments (Xiros; Leeds, UK) Polyethylene terephthalate (Smith et al. 2016; Smith et al. 2017)
ArthroFlex Arthrex (Naples, Florida) Processed human dermis (Beitzel et al. 2012; Petri et al. 2015)
Bio-Blanket Stryker Orthopaedics (Mahwah, New
Jersey)
Processed bovine dermis (Chen et al. 2009; Ricchetti et al.
2012; Rotini et al. 2011)
Conexa Tornier (Edina, Minnesota) Processed porcine dermis (Gupta et al. 2013; Shea et al. 2010;
Xu et al. 2012)
SportMesh Soft Tissue Reinforcement Biomet Sports Medicine (Warsaw,
Indiana)
Poly(urethaneurea) (Petriccioli et al. 2013; Barber and
Aziz-Jacobo 2009)
TissueMend Soft Tissue Repair Matrix TEI Biosciences (Boston, Massachusetts;
marketed by Stryker Orthopaedics,
Mahwah, New Jersey)
Collagen membrane derived
from fetal bovine dermis
(Chen et al. 2009; James et al. 2010;
Song et al. 2010)
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score (Nada et al. 2010). However, there were no controls
in this study.
Skeletal muscle
Clinical applications of muscle regeneration strategies
are very limited although the topic receives a substantial
amount of interest in basic science and preclinical stud-
ies (Corona and Greising 2016; Kwee and Mooney
2017). Restore Orthobiologic Implant (DePuy Orthopae-
dics; Warsaw, Indiana) was also used to treat a patient
with large volumetric muscle loss and the presence of
new tissue at the implant assessed by computer tomog-
raphy, showing an improvement in strength after the
surgery (Mase et al. 2010). Sicari et al. (Sicari et al. 2014)
used extracellular matrix scaffolds from porcine urinary
bladder to treat patients with volumetric muscle loss.
The scaffolds promoted the remodelling of muscle tissue
with perivascular stem cell homing and the de novo for-
mation of muscle cells, and functional improvements in
some patients (Sicari et al. 2014).
Articular cartilage
The current surgical treatments for articular cartilage
lesions include microfracture, mosaicplasty, cell implant-
ation, osteochondral allograft transfer arthroscopic
chondroplasty, and joint arthroplasty (Mollon et al.
2013). The fast spread of autologous chondrocyte im-
plantation (ACI) (Brittberg et al. 1994; Knutsen et al.
2016) and matrix-induced autologous chondrocyte
implantation (MACI) (Basad et al. 2010; Brittberg 2010)
indeed promote the growth of the concept of regenera-
tive tissue engineering with numerous papers, although,
hyaline-like cartilage is not evidenced by high-quality
clinical studies (Mollon et al. 2013).
The Medical Services Advisory Committee in Australia
performed an evidence-based assessment in their ACI/
MACI report accessible on http://www.msac.gov.au/inter
net/msac/publishing.nsf/Content/E72BFBEC5447F91FCA
25801000123B6D/$File/1140_Report_Final040211.pdf. It
was demonstrated that ACI/MACI is safe without serious
adverse effects. Nevertheless, the committee reported that
ACI/MACI or comparator treatments were not better
than non-surgical treatments in high-quality randomised
controlled trials. The effectiveness of ACI/MACI was
comparable to mosaicplasty and microfracture, i.e. the se-
lected comparator treatments, in terms of function, pain
relief, and life quality in short-medium term. The main
disadvantages over the comparator treatments are that
ACI/MACI requires two surgeries, chondrocytes dediffer-
entiate during in vitro culture, with costs reported to be of
14 k$ for biopsy and grafting procedure while mosaic-
plasty costs 2.6 k$ and microfracture 1.4 k$. On the other
hand, more recent studies provide evidence favouring
MACI over microfacture (Devitt et al. 2017; Saris et al.
2014). In the randomized clinical trial of Saris et al. (Saris
et al. 2014), MACI was reported to be clinically signifi-
cantly better than microfracture in the treatment of symp-
tomatic focal cartilage defects at least 3 cm2 in size at a
2-year follow-up, but the structural repair tissue was simi-
lar. A systematic review of the randomised controlled tri-
als (Devitt et al. 2017) showed that the defects larger than
4.5 cm2 treated with ACI/MACI had better outcomes than
with microfracture. Nevertheless, based on the available
evidence, no single treatment can be assigned to be the
most effective method. This review (Devitt et al. 2017) in-
cluded studies in which the patients were 18–55 years old
with an articular cartilage lesion with a size of 1–15 cm2
and an International Cartilage Repair Society grade of
II-IV that are not related to osteonecrosis, osteoarthritis,
nor inflammatory arthritis.
There are many products available (Table 2). The
strategies for cartilage regeneration may have a major
drawback including the fibrocartilage (and not hyaline)
nature of the neo-tissue. Improved strategies are still
needed for cartilage and the best cost-effective treatment
should be identified with more rigorous prospective,
with high quality randomised clinical trials (Vilela et al.
2015). Kreuz et al. (Kreuz et al. 2009) reported the clin-
ical outcome after a 4-year clinical follow-up (Fig. 2) of
the focal osteoarthritic knee cartilage defects that were
treated with BioSeed-C (BioTissue Technologies GmbH;
Freiburg,Germany), a second-generation autologous car-
tilage graft based on a bioresorbable two-component
gel-polymer scaffold. Significant improvement in the
Lysholm and International Cartilage Repair Society
(ICRS) scores were observed as early as 6 months but
remained unchanged during the follow-up. The Inter-
national Knee Documentation Committee (IKDC) score
and Osteoarthritis Outcome Score (KOOS) were also
improved. Magnetic resonance imaging (MRI) evaluation
showed moderately/completely filled defects while hyper
intense signals were seen in 16 out of 19 patients. There
was no improvement in the clinical and MRI scores 2
out of 19 patients (Kreuz et al. 2009).
Gobbi and Whyte (Gobbi and Whyte 2016) evaluated the
medium-term clinical outcomes of cartilage repair using a
single-stage technique of a hyaluronic acid-based scaffold
(Hyalofast; Anika Therapeutics, Abano Terme, Italy) with
bone marrow aspirate concentrate compared with micro-
fracture technique. At 2 years post-surgery, good clinical
outcomes were obtained with both techniques, while at
5 years post-surgery, patients from the microfracture group
could not maintain the improvement unlike patients from
the scaffold group (Gobbi and Whyte 2016).
The NeoCart implant is a cartilage scaffold from
type-I collagen (Histogenics, Waltham, Massachusetts)
designed to be seeded with autologous chondrocytes and
cultured in a bioreactor. Preliminary studies showed that it
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improves the function and pain relief, and works better
than microfracture (Crawford et al. 2012). Wakitani et al.
(Wakitani et al. 2007) treated cartilage defects with ex vivo
cultured autologous bone marrow mesenchymal cell that
were placed first embedded in a soluble type-I collagen
from bovine skin (Koken, Tokyo, Japan), then placed onto
a collagen sheet from porcine tendon (Gunze, Kyoto,
Japan), gelated, and further cultured for few days before
implantation. Clinical improvements were achieved at
6 months post-surgery, and at 12 months post-surgery the
defects were confirmed to be filled while one of the cases’
histology indicated a fibrocartilaginous tissue in the defect,
not hyaline cartilage (Wakitani et al. 2007). In a multicen-
ter randomised controlled trial (Shive et al. 2006), a
chitosan-glycerol phosphate-based hydrogel, BST-CarGel
(Piramal Healthcare Inc., Laval, Quebec, Canada) was re-
ported to be superior at 5 years than microfracture with
better tissue repair in quantity and quality while being
similar on Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) tool, showed that there
are no clinical differences between the BST-CarGel and
microfracture group.
Particulated Articular Cartilage products are also
commercially available. Cartilage Autograft Implantation
Table 2 Examples of commercial products for cartilage repair
Product Company Biomaterial + Cells References
Bioseed-C BioTissue Technologies
(Freiburg, Germany)
Polylactin/polydiaxanon/fibrin +
autologous chondrocytes
(Zeifang et al. 2010; Ossendorf et al. 2007;
Kreuz et al. 2011)
Chondrosphere (ACT3D-
CS/ARTHROCELL 3D)
Co.don (Teltow, Germany) No scaffold + Autologous chondrocytes (Becher et al. 2017; Fickert et al. 2012;
Siebold et al. 2018)
CaReS-1S Arthro Kinetics Biotechnology
(Krems, Austria)
Murine (rat tail) type-I collagen hydrogel
+ autologous chondrocytes
(Petri et al. 2013; Schneider et al. 2011)
Biocart II Histohenics (Waltham,
Massachusetts)
Fibrin/hyaluronic acid + autologous
chondrocytes
(Eshed et al. 2012; Nehrer et al. 2008)
Cartipatch Tissue Bank of France
(Lyon, France)
Agarose/alginate hydrogel + autologous
chondrocytes
(Selmi et al. 2008)
NeoCart Histogenics (Waltham,
Massachusetts)
Bovine type-I collagen + autologous
chondrocytes
(Anderson et al. 2017; Crawford et al.
2012; Crawford et al. 2009)
RevaFlex (DeNovo ET) Isto Technologies
(St. Louis, Missouri)
No scaffold + allogeneic juvenile
chondrocytes
(McCormick et al. 2013)
Novocart 3D TETEC Tissue Engineering
Technologies (Reutlingen,
Germany)
Bovine type-I collagen/chondroitin
sulphate + autologous chondrocytes
(Niethammer et al. 2014; Zak et al. 2014;
Niethammer et al. 2017)
Fig. 2 For implantation, BioSeed-C was armed from the corners with resorbable sutures secured by threefold knots (a), k-wires were drilled in the
corner of the defect (b), using the k-wires, the guiding threads were pulled through the femoral bone, and the knots were guided into the
subchondral bone (c), the knots functioned as anchors, seized the subchondral bone and fixed the implant (d), MRI showing the cartilage defect
at the medial femoral condyle before implantation (e) and after four years where the defect was completely filled (f), and the MRI shows a
patellar cartilage defect before implantation (g) and after four years where defect was completely filled (h). Adapted with a minor modification
from (Kreuz et al. 2009)
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System (CAIS) (DePuy Mitek, Raynham,Massachusetts)
is based on the distribution of autogenous cartilage tis-
sue pieces on a polycaprolactone/polyglycolic acid scaf-
fold. With DeNovoNatural Tissue (Zimmer, Warsaw,
Indiana), juvenile allograft cartilage pieces are fixed into
a defect with fibrin glue (Farr et al. 2012; Mollon et al.
2013). A randomised controlled trial (Cole et al. 2011)
compared CAIS and microfracture. CAIS patients had
significantly more improvements in the KOOS instru-
ment and IKDC score than the microfracture patients at
24 months post-operation (Cole et al. 2011).
Studies from Hunziker et al. (Hunziker et al. 2015),
Iwasa et al. (Iwasa et al. 2009), and Huang et al. (Huang
et al. 2016) are of importance as comprehensive reviews
on cartilage repair in the clinical situation. Although the
biomaterials and strategies differ slightly from each other,
none of the products’ outcome is satisfactory enough. It
can be concluded that it is not possible to deduct a clear
ranking of products, and a firm recommendation on the
preferred cartilage repair strategy cannot be made. As
already discussed in the previous section, the challenges
are many and should be overcome for a robust and novel
regenerative treatment of cartilage lesions.
Bone and osteochondral tissue
Given the composition of natural bone, ceramics alone
or combined with polymers found an ample space for
applications and provided limited acceptable outcomes
thanks to active biology within the bone, such as hy-
droxyapatite (e.g. Finblock; FinCeramica Faenza, Italy)
(Marcacci et al. 2007) and stem cell-loaded β-tricalcium
phosphate (β-TCP; Osferion Olympus Biomaterial,
Tokyo, Japan) (Kawate et al. 2006).
Oryan et al. comprehensively reviewed the bone grafts
and commercially available bone substitutes (which are
numerous and thus it is not within the scope of this re-
view to review each of them), and their clinical applica-
tions (Oryan et al. 2014). The autografts remain the gold
standard for bone regeneration by functioning superior
to tissue engineering scaffolds.
Sotome et al. (Sotome et al. 2016) reported the results
of a multicenter randomised controlled trial showing
that porous hydroxyapatite/collagen composite (Refit;
HOYATechnosurgical, Tokyo, Japan) was superior to por-
ous β-tricalcium phosphate implant (Osferion; Olympus,
Tokyo, Japan) for bone regeneration but with a relatively
higher incidence of adverse (although not serious) effects
as no implants were rejected (Sotome et al. 2016). For the
treatment of talar osteochondral lesions, two different
scaffolds were used to deliver bone marrow-derived cells
with a platelet gel. Based on the results of a minimum
follow-up of 24 months, both scaffolds (Spongostan Powder:
porcine collagen powder, Johnson & Johnson Medical,
Gargrave, Skipton, UK; and HYAFF-11: hyaluronic acid,
Fidia Advanced Biopolymers Laboratories, Abano Terme,
Italy) provided a similar improvement (Giannini et al. 2009).
Composites and multilayer scaffolds are of interest for
osteochondral tissue engineering where each layer is de-
signed for a particular tissue (Fig. 3). In the pilot clinical
trial of MaioRegen (Fin-Ceramica, Faenza, Italy) for the
treatment of 15 osteochondral defects (Fin-Ceramica,
Faenza, Italy), Kon et al. (Kon et al. 2010) reported
promising preliminary clinical results at short-term are
reported. In 13 defects, the scaffolds were completely
attached and a repair tissue was present, in 10 defects
the defects were completely filled at 6 months
post-implantation, and complete integration almost only
in half of the defects (in 8 defects). At 6 months
post-implantation, significant improvements in the
IKDC scores were reported although oedema or sclerosis
in the subchondral bone were found in 5 defects (Kon et
al. 2010). Altered MRI signal and a slow maturation
process were also reported (Kon et al. 2014). With The
TruFit CB scaffold (Smith & Nephew, Andover,
Massachusetts) (Melton et al. 2010), controversial clinical
and imaging outcomes were reported (Kon et al. 2014)
and its commercialisation suspended (Vilela et al. 2015).
Meniscus
The clinical management of meniscus lesions is some-
times challenging, with the primary intention to preserve
the meniscus as much as possible and repairing has pro-
vided good results in some cases; indications for scaf-
folds are limited (Cengiz et al. 2017b; Cengiz et al.
2017d; Pereira et al. 2016a; Pereira et al. 2016b). Two
scaffolds are available: i) bovine type-I collagen scaffold
(CMI; Ivy Sports Medicine, Lochhamer, Germany)
(Monllau et al. 2011; Zaffagnini et al. 2015; Zaffagnini et
al. 2011), and ii) polycaprolactone-polyurethane scaffold
(Actifit; Orteq Bioengineering, London, UK) (Fig. 4)
(Bouyarmane et al. 2014; Bulgheroni et al. 2013; Gelber
et al. 2015; Verdonk et al. 2012). The commercial scaf-
folds are safe without apparent adverse reactions and
somewhat positive functional and clinical results have
been achieved despite their limitations. However, when
native-like meniscus regeneration is questioned, there
are some outstanding issues to be addressed (matrix
composition and organisation of the neo-tissue). Never-
theless, the restoration of the fundamental function of
meniscus, i.e. the protection of cartilage, should be one
of the primary goals since obtaining a functionless repair
tissue will not help the patient in the long-term (Cengiz
et al. 2017b).
Due to their regenerative potential and regulatory and
practical advantage (Chahla et al. 2017), biologics includ-
ing platelet-rich plasma (PRP), bone marrow aspirate con-
centrate, hyaluronic acid, and stem cells (Gobbi et al.
2017; Narayanan et al. 2017) have been widely used in
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orthopaedics (Gobbi et al. 2017; Musahl et al. 2017; Utku
et al. 2015) including for bone (Malhotra et al. 2013), car-
tilage (Nakasa et al. 2017), meniscus (Cengiz et al. 2017a),
muscle (Canata et al. 2017), tendons (Canata et al. 2017),
and ligaments (Gobbi and Whyte 2017). Compared with
the use of scaffolds or ex vivo cultured cell therapies, the
clinical use of PRP is of relative practical and/or regulatory
convenience as it is autologous, minimally obtainable, and
relatively easy to apply. Given the fact that there are
numerous PRP usages (such as preparation protocol,
formulation, dosage, application technique), there are
inconsistencies in the clinical studies as systematically
reviewed by Chahla et al. (Chahla et al. 2017). The benefits
of PRP depend on the context (Andia and Maffulli 2013),
and thus some studies disagree with each other (Metcalf
et al. 2013; Piuzzi et al. 2017). Nourissat et al. (Nourissat
et al. 2013) pointed out that there is no evidence favouring
the use of PRP in arthroscopic surgery while a
meta-analysis (Sheth et al. 2012) showed that there was no
absolute evidence on the clinical usefulness of PRP in
orthopaedics.
Conclusions and final remarks
There have been several exciting advances in ortho-
paedic tissue engineering. Many lessons have been
learned. Some issues were already solved, but many still
need to be addressed while future problems may also
arise. Reaching and getting through a clinical trial is a
time-consuming, laborious, and expensive path, while all
these things get exponential once entering the operating
room. Based on the current evidence, there is a disequi-
librium between the demand and supply in the clinics,
and tissue engineering has still ample room to grow be-
fore delivering fully functional solutions. This mandatory
growth will be an outcome of the teamwork between the
scientific researchers, orthopaedic surgeons, research
funding bodies, industry, investors, governmental bodies,
and regulatory bodies. Orthopaedic tissues are 3D solid/
Fig. 3 An osteochondral scaffold (MaioRegen, Fin-Ceramica, Faenza, Italy) has a porous 3D tri-layer composite structure to mimic the
osteochondral tissue. The top layer (the red C) is for the cartilage tissue and made from type-I collagen, the transition layer (the red T) is for the
transition zone, subchondral bone, and is 60% from type-I collagen and 40% from magnesium-hydroxyapatite, and the bottom layer (the red B) is
for the bone tissue and is 30% from type-I collagen and 70% from magnesium-hydroxyapatite (a), a bilayer osteochondral scaffold (Agili-C;
CartiHeal, Israel) that is currently in clinical trial and made from aragonite and hyaluronic acid shape of cylinders, with a similar surgical technique
as the mosaic-like osteochondral transplantation. The top layer is for the cartilage tissue and is from aragonite and hyaluronic acid, and the
bottom layer is for bone tissue phase and is from calcium carbonate in the aragonite crystalline form (b), a bilayer scaffold (TruFit CB; Smith &
Nephew, Andover, Massachusetts) is from poly(lactic-co-glycolic acid), poly(glycolic acid) fibres, and calcium sulphate (c). Adapted with a minor
modification from (Kon et al. 2014)
Fig. 4 A photograph (a) and micro-structural image (b) of a commercially available polycaprolactone-polyurethane scaffold (Actifit; Orteq
Bioengineering, London, UK) for meniscus. The scale bar indicates 1 mm
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filled tissues that perform mechanically, thus scaffolds
are and will be an indispensable volume filling and
mechanically supporting component for large lesions.
Future scaffold-based regeneration strategies should be
evidenced to have: (i) superior tissue regeneration cap-
ability with excellent long-term clinical outcomes, and
(ii) comparable cost with the existing methods. For this,
the challenges should be recognised and addressed. Sys-
tematic reviews and meta-analyses are worthy and bring
original results from existing results. Although it may
not be so easy, a superior research and funding mind-set
seems to be necessary to encourage academic scientists
and clinicians to execute studies that seek long-term
outcomes, and high quality randomised clinical trials
that take many years and consume a tremendous
amount of money but yield only one paper eventually.
With its dynamic and enthusiastic nature, tissue engin-
eering may hopefully enable a major change in the clin-
ical management of orthopaedic disorders in the future,
and in particular to personalised approaches, with only
one ultimate goal – the healthier individuals.
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